You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 復星醫藥漲4.5% 成員企業萬邦醫藥肝素鈉注射液獲美國FDA批准
格隆匯1月14日丨 港股復星醫藥(2196.HK)盤中漲4.72%,報35.2港元;A股復星醫藥(600196.SH)盤中漲4.8%,報50元,總市值1281億元。近日,上海復星醫藥股份有限公司控股子公司萬邦醫藥收到美國FDA出具的現場檢查報吿(EIR),萬邦醫藥第二聯合廠房注射劑生產線4通過美國FDA現場檢查。萬邦醫藥第二聯合廠房注射劑生產線4承接生產的產品為肝素鈉注射液,並於日前收到了美國FDA簽發的PAS(批准前補充申請)批准信,這標誌着萬邦醫藥已具備向美國市場供應該注射劑生產線所涉產品肝素鈉注射液的資格。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account